02-19-2017  10:40 pm      •     

June 19, 2016 marks World Sickle Cell Day. In a desire to help create a greater awareness of sickle cell disease (SCD) and increase their efforts to find a cure, Pfizer invited members of the Black Press to meet and discuss with key members of their rare disease medical and management staff the state of (SCD) and their search for a cure.

It is estimated that sickle cell disease (SCD) affects approximately 100,000 Americans and 1 out of 365 Blacks in the United States, according to the Centers for Disease Control and Prevention. About 1 in 13 Blacks are born with sickle cell trait (SCT).

Sickle cell disease is one of the most prevalent genetic disorders in the U.S. It is a rare and debilitating chronic disease with lifelong clinical impact and reduced life expectancy; life expectancy is 48 years for females and 42 years for males with sickle cell disease.

There are more than 100,000 people in the U.S. living with sickle cell disease, and many of them experience multiple vaso-occlusive crises each year. These painful crises result in more than 75,000 hospitalizations per year in the U.S., with an average hospital stay of approximately six days.

Niesha Foster, the senior director and corporate affairs lead for Pfizer’s inflammation, immunology and rare disease unit, introduced the participants who shared why they’ve been so devoted to creating greater awareness about (SCD), and the opportunities available to assist those that struggle with this debilitating disease.

Sonja Banks, the CEO of the Sickle Cell Disease Association of America, Inc. (SCDAA) shared how alarmed she was to learn in 2010 that “in a hundred years of discovering the sickle cell disease, only one FDA drug had been approved and it wasn’t even for sickle cell. It was just as heart wrenching then, as it is now, to know that our people are still going to hospitals as their medical home. Why don’t we have a cure?”

Pfizer’s Chief Medical Officer Dr. Freda Lewis-Hall recalled the joy she initially felt interning at Howard University Hospital after graduating from medical school, but when she attempted to ease the pain of a toddler living with sickle cell, that joy was replaced with an overwhelming sense of futility.

“I heard an unbelievable piercing sound from a toddler in a sickle cell crisis,” said Lewis-Hall. “I tried to hydrate her and provide some pain relief…It was at that moment that I realized how helpless I was without the tools.”

Thirty years later, Lewis Hall said that physicians still lack the necessary tools to treat the disease.

Although some of the drugs that scientists have discovered have just not been good enough or safe enough, according to Lewis-Hall and Banks, the reason why a cure hasn’t been developed is because African Americans haven’t participated enough in clinical trials.

All of the participants, including Dr. Kevin Williams, the vice president of global medical affairs in Pfizer’s rare disease unit, recognized that African Americans are reluctant and often afraid to participate in clinical trials, because of the lingering distrust of the medical field due to the Tuskegee Syphilis Study and often poor treatment received at medical facilities.

Thomas Watkins, the publisher of the Daily Challenge, said “Blacks will participate in clinical trials as long as they’re not the only ones.”

Banks said that the African American community needs to get over the stigma associated with clinical trials.

“The syphilis study wouldn’t happen again,” said Banks. “We are too much of an educated community now … and who’s going to make these drugs come to fruition? If we don’t participate we’ll never find treatment or a cure.”

“A lot of people have no idea about what it means to participate in a clinical trial,” says Dr. Lewis Hall … Some of it is re-educating about the things that have happened in our collective African American past.

“We need to be educated specifically what it really means to be in a clinical trial,” said Lewis-Hall. “Our absolute best advocates are people who have been in clinical trials.”

Today’s clinical trials are also highly regulated by third party experts and require informed consent.

Marie Ojiambo, who is not only a SCD patient and Pfizer intern, but is also an advocate that works with SCDAA said that it’s easier for her to go to a SCD patient and get them to participate in a clinical trial than it is for a doctor.

There are 37,500 clinical trials currently available, said Dr. Lewis-Hall.

Pfizer is currently in Phase 3 of their clinical trial and needs to enroll 350 participants within the next 2 years. Since they’ve already obtained some positive results from their Phase 2 trials, they hope to have a drug available in 3-5 years.

Dr. Lewis-Hall explained that it usually takes 15 years to bring a new drug to trial. “So by the time that you get to Phase 3, it would be an unusual event for a company to walk away…and if this drug doesn’t make it because of a lack of participation, it would be a crying shame.”

For more information about clinical trials log on to www.clinicaltrials.gov or www.gethealthystayhealthy.com and click on the link, “Find a Trial.”

 

Joan H. Allen is the host of INSIDE NEW YORK and an editor at the Daily Challenge. Check out INSIDE NEW YORK via livestream at MNN.org. Follow Joan on Twitter and Facebook for program updates, giveaways and promotional offers.

Recently Published by The Skanner News

  • Default
  • Title
  • Date
  • Random
  • WASHINGTON (AP) — One month after the inauguration, the stretch of Pennsylvania Avenue in front of Donald Trump's White House still is a hard-hat zone. Skeletal remains of the inaugural reviewing stands poke skyward. Random piles of plywood and cables are heaped on the ground inside crooked lines of metal fencing. The disarray outside the president's front door, though not his fault, serves as a metaphor for the tumult still unfolding inside. Four weeks in, the man who says he inherited "a mess" at home and abroad is presiding over a White House that is widely described as itself being a mess. At a stunning pace, Trump has riled world leaders and frustrated allies. He was dealt a bruising legal blow on one of his signature policies. He lost his national security adviser and his pick for labor secretary to scandal. He's seen forces within his government push back against his policies and leak confidential information. All of this has played out amid a steady drip of revelations about an FBI investigation into his campaign's contacts with Russian intelligence officials. Trump says his administration is running like a "fine-tuned machine." He points to the rising stock market and the devotion of his still-loyal supporters as evidence that all is well, although his job approval rating is much lower than that for prior presidents in their first weeks in office. Stung by the unrelenting criticism coming his way, Trump dismisses much of it as "fake news" delivered by "the enemy of the people" — aka the press. Daily denunciations of the media are just one of the new White House fixtures Americans are adjusting to. Most days start (and end) with presidential tweets riffing off of whatever's on TV talk shows or teasing coming events or hurling insults at the media. At some point in the day, count on Trump to cast back to the marvels of his upset of Democrat Hillary Clinton in the November election and quite possibly overstate his margins of support. Expect more denunciations of the "dishonest" press and its "fake news." From there, things can veer in unexpected directions as Trump offers up policy pronouncements or offhand remarks that leave even White House aides struggling to interpret them. The long-standing U.S. policy of seeking a two-state solution to the Israeli-Palestinian conflict? Trump this past week offered this cryptic pronouncement: "I'm looking at two-state and one-state, and I like the one that both parties like. I can live with either one." His U.N. ambassador, Nikki Haley, the next day insisted, "We absolutely support a two-state solution." Trump's days are busy. Outside groups troop in for "listening sessions." Foreign leaders call or come to visit. (Or, in the case of Mexico's president, cancel out in pique over Trump's talk about the planned border wall.) After the president signed two dozen executive actions, the White House was awaiting a rush order of more of the gold-plated Cross pens that Trump prefers to the chrome-plated ones used by his predecessor. Trump hands them out as souvenirs at the signing ceremonies that he points to as evidence of his ambitious pace. "This last month has represented an unprecedented degree of action on behalf of the great citizens of our country," Trump said at a Thursday news conference. "Again, I say it. There has never been a presidency that's done so much in such a short period of time." That's all music to the ears of his followers, who sent him to Washington to upend the established order and play the role of disrupter. "I can't believe there's actually a politician doing what he says he would do," says an approving Scott Hiltgen, a 66-year-old office furniture sales broker from River Falls, Wisconsin. "That never happens." Disrupt Trump has. But there may be more sound and fury than substance to many of his early actions. Trump did select Judge Neil Gorsuch to replace the late Antonin Scalia on the Supreme Court, a nomination that has drawn strong reviews from conservatives. But the president is regrouping on immigration after federal judges blocked his order to suspend the United States' refugee program and ban visitors from seven Muslim-majority countries, which had caused chaos for travelers around the globe. Some other orders on issues such as the U.S.-Mexico border wall and former President Barack Obama's health care law are of limited effect. Trump says his early actions show he means to deliver on the promises he made during the campaign. "A lot of people say, 'Oh, oh, Trump was only kidding with the wall,'" the president told a group of police chiefs recently. "I wasn't kidding. I don't kid." But the Republican-led Congress is still waiting to see specifics on how Trump wants to proceed legislatively on top initiatives such as replacing the health care law, enacting tax cuts and revising trade deals. The messy rollout of the travel ban and tumult over the ouster of national security adviser Michael Flynn for misrepresenting his contacts with Russia are part of a broader state of disarray as different figures in Trump's White House jockey for power and leaks reveal internal discord in the machinations of the presidency. "I thought by now you'd at least hear the outlines of domestic legislation like tax cuts," says Princeton historian Julian Zelizer. "But a lot of that has slowed. Trump shouldn't mistake the fact that some of his supporters like his style with the fact that a lot of Republicans just want the policies he promised them. He has to deliver that." Put Senate Majority Leader Mitch McConnell, R-Ky., in the camp of those more interested in substance than style. "I'm not a great fan of daily tweets," McConnell said Friday, referring to the "extra discussion" that Trump likes to engage in. But McConnell was quick to add: "What I am a fan of is what he's been actually doing." He credits Trump with assembling a conservative Cabinet and taking steps to reduce government regulation, and promised: "We like his positions and we're going to pursue them as vigorously as we can." The challenge may be to tease out exactly what Trump wants in the way of a health care plan, tax changes and trade policy. At his long and defiant news conference on Thursday, Trump tried to dispel the impression of a White House in crisis, squarely blaming the press for keeping him from moving forward more decisively on his agenda. Pointing to his chief of staff, Reince Priebus, Trump said, "You take a look at Reince, he's working so hard just putting out fires that are fake fires. I mean, they're fake. They're not true. And isn't that a shame because he'd rather be working on health care, he'd rather be working on tax reform." For all the frustrations of his early days as president, Trump still seems tickled by the trappings of his office. When New Jersey Gov. Chris Christie visited the White House last week to discuss the national opioid epidemic over lunch, the governor said Trump informed him: "Chris, you and I are going to have the meatloaf.'" Trump added: "I'm telling you, the meatloaf is fabulous." ___Follow Nancy Benac on Twitter at http://twitter.com/nbenac
    Read More
  • FDR executive order sent 120,000 Japanese immigrants and citizens into camps
    Read More
  • Pruitt's nomination was strongly opposed by environmental groups and hundreds of former EPA employees
    Read More
load morehold SHIFT key to load allload all